Morgan Stanley Maintains Enfusion(ENFN.US) With Buy Rating, Maintains Target Price $11
Stifel Maintains Enfusion(ENFN.US) With Buy Rating, Raises Target Price to $11
Enfusion: Strong Client Acquisitions and Strategic Positioning Drive Buy Rating
William Blair Maintains Enfusion(ENFN.US) With Buy Rating
William Blair Remains a Buy on Enfusion (ENFN)
Analysts' Opinions Are Mixed on These Technology Stocks: International Business Machines (IBM), Salesforce (CRM) and Enfusion (ENFN)
William Blair Maintains Enfusion(ENFN.US) With Buy Rating
William Blair Sticks to Their Buy Rating for Enfusion (ENFN)
Buy Rating Affirmed for Enfusion on Strong Growth and Market Positioning Prospects
Analysts Offer Insights on Technology Companies: Enfusion (ENFN), Vertex (VERX) and Shift4 Payments (FOUR)
Enfusion (ENFN) Gets a Buy From William Blair
Piper Sandler Reaffirms Their Hold Rating on Enfusion (ENFN)
Enfusion's Growth Strategy Met With Sell Rating Amid Market and Strategic Challenges
Analysts' Opinions Are Mixed on These Technology Stocks: GoDaddy (GDDY) and Enfusion (ENFN)
Stifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)
Enfusion (ENFN) Gets a Hold From Piper Sandler
Analysts Have Conflicting Sentiments on These Technology Companies: Marvell (MRVL) and Enfusion (ENFN)
Enfusion (ENFN) Gets a Buy From William Blair
Enfusion Analyst Ratings
B of A Securities Maintains Underperform on Enfusion, Raises Price Target to $9